227 related articles for article (PubMed ID: 29334798)
1. Vulvar vestibular effects of ospemifene: a pilot study.
Murina F; Di Francesco S; Oneda S
Gynecol Endocrinol; 2018 Jul; 34(7):631-635. PubMed ID: 29334798
[TBL] [Abstract][Full Text] [Related]
2. Coital pain in the elderly: could a low dose estriol gel thrill the vulvar vestibule?
Murina F; Graziottin A; Felice R; Di Francesco S
Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():121-124. PubMed ID: 27838536
[TBL] [Abstract][Full Text] [Related]
3. Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.
Simon JA; Altomare C; Cort S; Jiang W; Pinkerton JV
J Womens Health (Larchmt); 2018 Jan; 27(1):14-23. PubMed ID: 29064335
[TBL] [Abstract][Full Text] [Related]
4. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.
Portman DJ; Bachmann GA; Simon JA;
Menopause; 2013 Jun; 20(6):623-30. PubMed ID: 23361170
[TBL] [Abstract][Full Text] [Related]
5. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
Portman D; Palacios S; Nappi RE; Mueck AO
Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.
Wurz GT; Kao CJ; DeGregorio MW
Clin Interv Aging; 2014; 9():1939-50. PubMed ID: 25419123
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women.
Simon J; Portman D; Mabey RG;
Maturitas; 2014 Mar; 77(3):274-81. PubMed ID: 24411556
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis.
Cui Y; Zong H; Yan H; Li N; Zhang Y
J Sex Med; 2014 Feb; 11(2):487-97. PubMed ID: 24251418
[TBL] [Abstract][Full Text] [Related]
9. Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy.
Bruyniks N; Nappi RE; Castelo-Branco C; de Villiers TJ; Simon J
Climacteric; 2016; 19(1):60-5. PubMed ID: 26669628
[TBL] [Abstract][Full Text] [Related]
10. Ospemifene efficacy and safety data in women with vulvovaginal atrophy.
Pup LD; Sánchez-Borrego R
Gynecol Endocrinol; 2020 Jul; 36(7):569-577. PubMed ID: 32329400
[TBL] [Abstract][Full Text] [Related]
11. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy.
Nappi RE; Panay N; Bruyniks N; Castelo-Branco C; De Villiers TJ; Simon JA
Climacteric; 2015 Apr; 18(2):233-40. PubMed ID: 25335119
[TBL] [Abstract][Full Text] [Related]
12. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.
McLendon AN; Clinard VB; Woodis CB
Pharmacotherapy; 2014 Oct; 34(10):1050-60. PubMed ID: 25052122
[TBL] [Abstract][Full Text] [Related]
13. Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use.
Pinkerton JV; Kagan R
Expert Opin Pharmacother; 2015; 16(17):2703-14. PubMed ID: 26634778
[TBL] [Abstract][Full Text] [Related]
14. Ospemifene plus fractional CO
Murina F; Felice R; Di Francesco S; Nelvastellio L; Cetin I
Gynecol Endocrinol; 2020 May; 36(5):431-435. PubMed ID: 31637943
[TBL] [Abstract][Full Text] [Related]
15. Assessment of ospemifene or lubricants on clinical signs of VVA.
Constantine G; Graham S; Koltun WD; Kingsberg SA
J Sex Med; 2014 Apr; 11(4):1033-1041. PubMed ID: 24443923
[TBL] [Abstract][Full Text] [Related]
16. Effects of ospemifene on genitourinary health assessed by prospective vulvar-vestibular photography and vaginal/vulvar health indices.
Goldstein I; Simon JA; Kaunitz AM; Altomare C; Yoshida Y; Zhu J; Schaffer S; Soulban G
Menopause; 2019 Sep; 26(9):994-1001. PubMed ID: 31453961
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Two Laser Treatment Strategies for Breast Cancer Survivors With Genitourinary Syndrome of Menopause.
Okui N; Okui M; Kouno Y; Nakano K; Gambacciani M
Cureus; 2023 May; 15(5):e38604. PubMed ID: 37284382
[TBL] [Abstract][Full Text] [Related]
18. Profile of ospemifene in the breast.
Berga SL
Reprod Sci; 2013 Oct; 20(10):1130-6. PubMed ID: 23945733
[TBL] [Abstract][Full Text] [Related]
19. [Use of transcutaneous electrical stimulation and biofeedback for the treatment of vulvodynia (vulvar vestibular syndrome): result of 3 years of experience].
Dionisi B; Anglana F; Inghirami P; Lippa P; Senatori R
Minerva Ginecol; 2008 Dec; 60(6):485-91. PubMed ID: 18981976
[TBL] [Abstract][Full Text] [Related]
20. Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy.
DeGregorio MW; Zerbe RL; Wurz GT
Steroids; 2014 Nov; 90():82-93. PubMed ID: 25087944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
